false
0001034842
0001034842
2024-03-05
2024-03-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): March 5, 2024
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889 |
|
94-3248524 |
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
611 Gateway Boulevard |
|
|
Suite 900 |
|
|
South San Francisco, CA |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on
Which Registered |
Common Stock, par value $0.001 per share |
|
RIGL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. |
Results of Operations and Financial Condition. |
On March 5, 2024, Rigel
Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its fourth quarter and year ended December 31,
2023. A copy of Rigel’s press release, titled “Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides
Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
The information in this
report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into
any filing with the U.S. Securities and Exchange Commission made by Rigel, whether made before or after the date hereof, regardless of
any general incorporation language in such filing.
Item 9.01. |
Financial Statements and Exhibits. |
|
|
(d) |
Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 5, 2024 |
RIGEL PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Ray Furey, J.D. |
|
|
Ray Furey, J.D. |
|
|
Executive Vice President, General Counsel and Corporate Secretary |
Exhibit
99.1
Rigel
Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
| · | Fourth
quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net
product sales of $25.7 million and REZLIDHIA® net product sales of $3.9
million |
| · | Expanded
product portfolio with acquisition of U.S. rights to GAVRETO®, an
FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small
cell lung cancer and advanced or metastatic thyroid cancer |
| · | Conference
call and webcast scheduled today at 4:30 p.m. Eastern Time |
SOUTH
SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results
for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSE® (fostamatinib disodium
hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to
a previous treatment and sales of REZLIDHIA® (olutasidenib)
capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate
dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
“In
2023, fueled by increased physician awareness and adoption for both TAVALISSE and REZLIDHIA, we achieved net product sales of $104.3
million, an increase of 36% compared to 2022,” said Raul Rodriguez, Rigel’s president and CEO. “We recently expanded
our hematology and oncology portfolio with the addition of GAVRETO, a U.S. marketed product for the treatment of RET fusion-positive
NSCLC. This addition is highly synergistic with our current portfolio and existing infrastructure, which we believe will further support
top line growth. In 2024, we are focused on commercial expansion and
execution, while advancing our pipeline with more strategic collaborations like MD Anderson and CONNECT.”
Business
Update
| · | In
the fourth quarter of 2023, we achieved the highest number of TAVALISSE bottles shipped to
patients and clinics in a quarter since launch. A total of 2,671 bottles were sold in the
U.S., 2,463 of which were shipped directly to patients and clinics. For
the full year ended December 31, 2023, 9,396 bottles of TAVALISSE were shipped directly
to patients and clinics, representing an increase of 16% compared to 2022. |
| · | During
the fourth quarter of 2023, we achieved 47% growth in total REZLIDHIA bottles sold compared
to the third quarter of 2023. A total of 308 bottles were sold in the U.S., 278 of which
were shipped directly to patients and clinics. For
the full year ended December 31, 2023, 795 bottles of REZLIDHIA were shipped directly
to patients and clinics. |
| · | In
February 2024, Rigel announced the acquisition of the U.S. rights to GAVRETO®
(pralsetinib). GAVRETO
is a once daily, small molecule, oral, kinase inhibitor of wild-type RET (rearranged during
transfection) and oncogenic RET fusions. GAVRETO is approved by the U.S. Food and Drug Administration
(FDA) for the treatment of adult patients with metastatic RET fusion-positive non-small cell
lung cancer (NSCLC) and advanced thyroid cancer. The acquisition of this product further
expands Rigel’s portfolio and leverages Rigel’s existing infrastructure in both
the institutional and community medical practice settings. Rigel expects to complete the
transition of the asset and start recognizing product sales in the third quarter of 2024. |
| · | In
January 2024, Rigel and CONNECT
announced a strategic development collaboration
to evaluate REZLIDHIA (olutasidenib) in combination with temozolomide as maintenance therapy
in patients with high-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation.
Under the collaboration, CONNECT will include olutasidenib in CONNECT’s TarGeT-D, a
molecularly guided Phase 2 umbrella clinical trial for HGG. The Rigel-sponsored arm will
study post-radiotherapy administration of olutasidenib in combination with temozolomide followed
by olutasidenib monotherapy as maintenance treatment in newly diagnosed pediatric and young
adult patients (<39 years old) with IDH1 mutation positive HGG, including diffuse intrinsic
pontine glioma (DIPG), an aggressive brain tumor with limited treatment options. Rigel will
provide CONNECT funding up to $3 million and study material over the four-year collaboration. |
| · | In
December 2023, Rigel and The
University of Texas MD Anderson Cancer Center (MD Anderson) announced
a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA
(olutasidenib) in acute myeloid leukemia (AML)
and other hematologic cancers. Under the strategic collaboration, Rigel and MD Anderson will
evaluate the potential of olutasidenib to treat newly diagnosed and relapsed or refractory
(R/R) patients with AML, higher-risk myelodysplastic syndromes (MDS), and advanced myeloproliferative
neoplasms (MPN), in combination with other agents. The collaboration will also support
the evaluation of olutasidenib as monotherapy in lower-risk
MDS and maintenance therapy in post-hematopoietic stem cell transplant (HSCT) patients.
Rigel will provide MD Anderson $15 million in time-based milestone
payments and study material over the five-year collaboration. |
| · | In
December 2023, Rigel also presented four posters highlighting data from the Company’s
commercial and clinical-stage hematology-oncology portfolio at the 65th American Society
of Hematology Annual Meeting and Exposition. Included was a poster, Abstract #2888,
reporting post hoc analyses in a subset of patients with mIDH1 R/R AML or MDS that
were R/R to HSCT, ivosidenib, or venetoclax. The analyses suggest that olutasidenib alone
or in combination with azacitidine may induce complete remissions in these patients. |
Financial
Update
For
the fourth quarter of 2023, Rigel reported a net income of $0.7 million, or $0.00 per basic and diluted share, compared to a net income
of $1.4 million, or $0.01 per basic and diluted share, for the same period of 2022.
For
the fourth quarter of 2023, total revenues were $35.8 million, consisting of $25.7 million in TAVALISSE net product sales, $3.9 million
in REZLIDHIA net product sales, $6.2 million in contract revenue from collaborations, and $0.1 million in government contract revenue.
TAVALISSE net product sales of $25.7 million represents a 17% increase compared to $21.9 million in the same period of 2022. REZLIDHIA
net product sales were $3.9 million compared to $0.9 million in the same period of 2022. Contract revenue from collaborations for the
fourth quarter of 2023 consisted of $3.7 million of revenue from Grifols S.A. (Grifols) and $0.3 million of revenue from Medison Pharma
Trading AG (Medison) related to delivery of drug supplies and earned
royalties, as well as $2.2 million of revenue from Kissei Pharmaceutical Co., Ltd. (Kissei) related to delivery of drug supplies.
For
the fourth quarter of 2023, total costs and expenses were $33.8 million, compared to $49.2 million for the same period of 2022. The decrease
in costs and expenses was partly due to decreased research and development costs due to the timing of trial completion activities related
to the Phase 3 clinical trials of fostamatinib in patients with COVID-19 and wAIHA, as well as the timing of clinical trial activities
related to the IRAK 1/4 inhibitor program. In addition, the decrease was also due to lower facility-related costs, and a milestone payment
to Forma Therapeutics Inc. (Forma), now Novo Nordisk, recorded as in-process research and development (IPR&D) included within cost
and expenses in the fourth quarter of 2022.
For
the full year 2023, Rigel reported a net loss of $25.1 million, or $0.14 per basic and diluted share, compared to a net loss of $58.6
million, or $0.34 per basic and diluted share, for the full year 2022.
For
the full year 2023, total revenues were $116.9 million, consisting of $93.7 million in TAVALISSE net product sales, $10.6 million in
REZLIDHIA net product sales, $11.5 million in contract revenue from collaborations, and $1.1 million in government contract revenue.
TAVALISSE net product sales of $93.7 million represents a 24% increase compared to $75.8 million in full year 2022. REZLIDHIA net product
sales of $10.6 million increased by $9.7 million compared to $0.9 million in the full year 2022. Contract revenue from collaborations
for the full year 2023, consisted of $8.8 million of revenue from Grifols related to the delivery of drug supplies and earned royalties,
$2.2 million of revenue from Kissei related to the delivery of drug supplies, and $0.5 million of revenue from Medison related to delivery
of drug supplies, earned royalties, and a milestone payment. Government contract revenue for the full year 2023 was primarily related
to income recognized in the second quarter of 2023 pursuant to the agreement with the U.S. Department of Defense to support Rigel’s
Phase 3 clinical trial of fostamatinib in high-risk hospitalized patients with COVID-19.
For
the full year 2023, total costs and expenses were $137.4 million, compared to $175.8 million for the full year 2022. The decrease in
costs and expenses was partly due to decreased research and development costs due to the completion of trial activities related to the
Phase 3 clinical trials of fostamatinib in patients with COVID-19 and wAIHA, as well as timing of clinical trial activities related to
the IRAK 1/4 inhibitor program. In addition, the decrease was also due to lower facility-related costs, and an upfront and a milestone
payment to Forma recorded as IPR&D included within cost and expenses in the full year 2022.
As
of December 31, 2023, Rigel had cash, cash equivalents and short-term investments of $56.9 million, compared to $58.2 million as
of December 31, 2022.
Conference
Call and Webcast with Slides Today at 4:30pm Eastern Time
Rigel
will hold a live conference call and webcast today at 4:30pm Eastern Time (1:30pm Pacific Time).
Participants
can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). The conference call will
also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com.
The webcast will be archived and available for replay after the call via the Rigel website.
About
ITP
In
patients with ITP (immune thrombocytopenia), the immune system attacks and destroys the body's own blood platelets, which play an active
role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. People suffering with chronic ITP may
live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies
for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing
therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.
About
AML
Acute
myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop
into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American
Cancer Society estimates that there will be about 20,800 new cases in the United States, most in adults, in 2024.1
Relapsed
AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.2 Refractory
AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after
intensive treatment.3 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated
treatments in relapsed or refractory disease remain an unmet need.
About
NSCLC
It
is estimated that over 230,000 adults in the U.S. will be diagnosed with lung cancer in 2024. Lung cancer is the leading cause
of cancer death in the U.S, with NSCLC being the most common type accounting for 80-85% of all lung cancer diagnoses.4
RET fusions are implicated in approximately 1-2% of patients with NSCLC.5
About
TAVALISSE®
Indication
TAVALISSE
(fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune
thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Important
Safety Information
Warnings
and Precautions
| · | Hypertension
can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible
to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly,
and adjust or initiate antihypertensive therapy for blood pressure control maintenance during
therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation
may be required. |
| · | Elevated
liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly
during treatment. If ALT or AST increase to ≥3 x upper limit of normal, manage hepatotoxicity
using TAVALISSE interruption, reduction, or discontinuation. |
| · | Diarrhea
occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE.
Monitor patients for the development of diarrhea and manage using supportive care measures
early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce
dose or discontinue TAVALISSE. |
| · | Neutropenia
occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of
patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with
TAVALISSE interruption, reduction, or discontinuation. |
| · | TAVALISSE
can cause fetal harm when administered to pregnant women. Advise pregnant women the potential
risk to a fetus. Advise females of reproductive potential to use effective contraception
during treatment and for at least 1 month after the last dose. Verify pregnancy status prior
to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human
milk. Because of the potential for serious adverse reactions in a breastfed child, advise
a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after
the last dose. |
Drug
Interactions
| · | Concomitant
use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite
of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities
that may require a reduction in TAVALISSE dose. |
| · | It
is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces
exposure to R406. |
| · | Concomitant
use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require
a dose reduction of the CYP3A4 substrate drug. |
| · | Concomitant
use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and
P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of
the BCRP and P-gp substrate drug. |
Adverse
Reactions
| · | Serious
adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea,
pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition,
severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia,
arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache,
syncope, and hypoxia (all 1%). |
| · | Common
adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea,
hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal
pain, fatigue, chest pain, and neutropenia. |
Please
see www.TAVALISSEUSPI.com for Full Prescribing Information.
To
report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch
or call 1-800-FDA-1088 (800-332-1088).
TAVALISSE
is a registered trademark of Rigel Pharmaceuticals, Inc.
About
REZLIDHIA®
INDICATION
REZLIDHIA
is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate
dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
IMPORTANT
SAFETY INFORMATION
WARNING:
DIFFERENTIATION SYNDROME
Differentiation
syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial
effusion, kidney injury, hypotension, fever, and weight gain. If differentiation syndrome is suspected, withhold REZLIDHIA and initiate
treatment with corticosteroids and hemodynamic monitoring until symptom resolution.
WARNINGS
AND PRECAUTIONS
Differentiation
Syndrome
REZLIDHIA
can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome
occurred in 16% of patients, with grade 3 or 4 differentiation syndrome occurring in 8% of patients treated, and fatalities in 1% of
patients. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening
or fatal. Symptoms of differentiation syndrome in patients treated with REZLIDHIA included leukocytosis, dyspnea, pulmonary infiltrates/pleuropericardial
effusion, kidney injury, fever, edema, pyrexia, and weight gain. Of the 25 patients who experienced differentiation syndrome, 19 (76%)
recovered after treatment or after dose interruption of REZLIDHIA. Differentiation syndrome occurred as early as 1 day and up to 18 months
after REZLIDHIA initiation and has been observed with or without concomitant leukocytosis.
If
differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg
IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms. If concomitant leukocytosis is observed, initiate
treatment with hydroxyurea, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms. Differentiation
syndrome may recur with premature discontinuation of corticosteroids and/or hydroxyurea treatment. Institute supportive measures and
hemodynamic monitoring until improvement; withhold dose of REZLIDHIA and consider dose reduction based on recurrence.
Hepatotoxicity
REZLIDHIA
can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased
blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory AML who received REZLIDHIA, hepatotoxicity
occurred in 23% of patients; 13% experienced grade 3 or 4 hepatotoxicity. One patient treated with REZLIDHIA in combination with azacitidine
in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury. The
median time to onset of hepatotoxicity in patients with relapsed or refractory AML treated with REZLIDHIA was 1.2 months (range: 1 day
to 17.5 months) after REZLIDHIA initiation, and the median time to resolution was 12 days (range: 1 day to 17 months). The most common
hepatotoxicities were elevations of ALT, AST, blood alkaline phosphatase, and blood bilirubin.
Monitor
patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine,
or jaundice. Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once
every other week for the third month, once in the fourth month, and once every other month for the duration of therapy. If hepatic dysfunction
occurs, withhold, reduce, or permanently discontinue REZLIDHIA based on recurrence/severity.
ADVERSE
REACTIONS
The
most common (≥20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase
increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia,
constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased,
mucositis, diarrhea and transaminitis.
DRUG
INTERACTIONS
| · | Avoid
concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. |
| · | Avoid
concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed
in the substrates prescribing information. If concomitant use is unavoidable, monitor patients
for loss of therapeutic effect of these drugs. |
LACTATION
Advise
women not to breastfeed during treatment with REZLIDHIA and for 2 weeks after the last dose.
GERIATRIC
USE
No
overall differences in effectiveness were observed between patients 65 years and older and younger patients. Compared to patients younger
than 65 years of age, an increase in incidence of hepatotoxicity and hypertension was observed in patients ≥65 years of age.
HEPATIC
IMPAIRMENT
In
patients with mild or moderate hepatic impairment, closely monitor for increased probability of differentiation syndrome.
Click
here for Full Prescribing Information, including Boxed WARNING.
To
report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch
or call 1-800-FDA-1088 (800-332-1088).
REZLIDHIA
is a registered trademark of Rigel Pharmaceuticals, Inc.
About
GAVRETO® (pralsetinib)
INDICATIONS
GAVRETO (pralsetinib)
is indicated for the treatment of:
| · | Adult
patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell
lung cancer (NSCLC) as detected by an FDA-approved test |
| · | Adult
and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive
thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if
radioactive iodine is appropriate)* |
*This
indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
IMPORTANT
SAFETY INFORMATION
| · | Interstitial
Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal ILD/pneumonitis
can occur in patients treated with GAVRETO. Pneumonitis occurred in 12% of patients who received
GAVRETO, including 3.3% with Grade 3-4, and 0.2% with fatal reactions. Monitor for pulmonary
symptoms indicative of ILD/pneumonitis. Withhold GAVRETO and promptly investigate for ILD
in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea,
cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity
of confirmed ILD. |
| · | Hypertension: Occurred
in 35% of patients, including Grade 3 hypertension in 18% of patients. Overall, 8% had their
dose interrupted and 4.8% had their dose reduced for hypertension. Treatment-emergent hypertension
was most commonly managed with anti-hypertension medications. Do not initiate GAVRETO in
patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO.
Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated.
Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently
discontinue GAVRETO based on the severity. |
| · | Hepatotoxicity: Serious
hepatic adverse reactions occurred in 1.5% of patients treated with GAVRETO. Increased aspartate
aminotransferase (AST) occurred in 49% of patients, including Grade 3 or 4 in 7% and increased
alanine aminotransferase (ALT) occurred in 37% of patients, including Grade 3 or 4 in 4.8%.
The median time to first onset for increased AST was 15 days (range: 5 days to 2.5 years)
and increased ALT was 24 days (range: 7 days to 3.7 years). Monitor AST and ALT prior to
initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and
as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on
severity. |
| · | Hemorrhagic
Events: Serious, including fatal, hemorrhagic events can occur with GAVRETO. Grade
≥3 events occurred in 4.1% of patients treated with GAVRETO including one patient with
a fatal hemorrhagic event. Permanently discontinue GAVRETO in patients with severe or life-threatening
hemorrhage. |
| · | Tumor
Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary
thyroid carcinoma receiving GAVRETO. Patients may be at risk of TLS if they have rapidly
growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients
at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated. |
| · | Risk
of Impaired Wound Healing: Impaired wound healing can occur in patients who receive
drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore,
GAVRETO has the potential to adversely affect wound healing. Withhold GAVRETO for at least
5 days prior to elective surgery. Do not administer for at least 2 weeks following major
surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution
of wound healing complications has not been established. |
| · | Embryo-Fetal
Toxicity: Based on findings from animal studies and its mechanism of action, GAVRETO
can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the
potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal
contraception during treatment with GAVRETO and for 2 weeks after the last dose. Advise males
with female partners of reproductive potential to use effective contraception during treatment
with GAVRETO and for 1 week after the last dose. |
| · | Common
adverse reactions (≥25%) were musculoskeletal pain, constipation, hypertension,
diarrhea, fatigue, edema, pyrexia, and cough. Common Grade 3/4 laboratory abnormalities
(≥2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin,
decreased phosphate, decreased leukocytes, decreased sodium, increased aspartate aminotransferase
(AST), increased alanine aminotransferase (ALT), decreased calcium (corrected), decreased
platelets, increased alkaline phosphatase, increased potassium, decreased potassium, and
increased bilirubin. |
| · | Avoid
coadministration of GAVRETO with strong or moderate CYP3A inhibitors, P-gp inhibitors,
or combined P-gp and strong or moderate CYP3A inhibitors. If coadministration cannot
be avoided, reduce the GAVRETO dose. Avoid coadministration of GAVRETO with strong
or moderate CYP3A inducers. If coadministration cannot be avoided, increase the GAVRETO
dose. |
| · | Lactation: Advise
women not to breastfeed during treatment with GAVRETO and for 1 week after the last dose. |
| · | Pediatric
Use: Monitor open growth plates in adolescent patients. Consider interrupting or
discontinuing GAVRETO if abnormalities occur. |
You
may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Genentech at 1-888-835-2555.
Please
click here to see the full Prescribing Information
and Patient Information for GAVRETO.
About
Rigel
Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies
that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San
Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
| 1. | The
American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). Revised January 17,
2024. Accessed Feb. 19, 2024: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html |
| 2. | Leukaemia
Care. Relapse in Acute Myeloid Leukaemia (AML). Version 3. Reviewed October 2021. Accessed
Feb 19, 2024: https://media.leukaemiacare.org.uk/wp-content/uploads/Relapse-in-Acute-Myeloid-Leukaemia-AML-Web-Version.pdf |
| 3. | Thol
F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid
leukemia. Blood (2015) 126 (3): 319-27. doi: https://doi.org/10.1182/blood-2014-10-551911 |
| 4. | The
American Cancer Society. Key Statistics for Lung Cancer. Revised November 20, 2023.
Accessed February 7, 2024: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html |
| 5. | Kato,
S. et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients.
Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679 |
Forward
Looking Statements
This
press release contains forward-looking statements relating to, among other things, expected
commercial and financial results, expectations related to
the potential and market opportunity of olutasidenib as therapeutics for R/R
AML and other conditions, the commercialization of fostamatinib or olutasidenib in the U.S. and international markets, the transition
and commercialization of pralsetinib for the treatment of non-small cell lung cancer and advanced thyroid cancer and Rigel's ability
to further develop its clinical stage product candidates and Rigel's partnering and collaboration efforts, including the progress of
Phase 1b clinical trial of R289 for the treatment of lower-risk myeloid dysplastic syndrome, olutasidenib’s evaluation in acute
myeloid leukemia (AML) and other hematologic cancers, and in newly diagnosed pediatric and young adult patients with high-grade glioma
(HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation. Any
statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
Forward-looking statements can be identified by words such as "plan", "potential", "may", "expects",
"will" and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently
involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are
outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the
timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties,
which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib or olutasidenib;
risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding fostamatinib
or olutasidenib; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials;
risks that fostamatinib or olutasidenib may have unintended side effects, adverse reactions or incidents of misuses; the availability
of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's
reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30,
2023 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information
currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking
statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments
or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein, except as required by law.
Contact
for Investors & Media:
Investors:
Rigel
Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David
Rosen
Argot
Partners
212.600.1902
david.rosen@argotpartners.com
RIGEL
PHARMACEUTICALS, INC.
STATEMENTS
OF OPERATIONS
(in
thousands, except per share amounts)
| |
Three
Months Ended December 31, | | |
Year
Ended December 31, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
(unaudited) | | |
| | |
| |
Revenues: | |
| | | |
| | | |
| | | |
| | |
Product
sales, net | |
$ | 29,539 | | |
$ | 22,783 | | |
$ | 104,294 | | |
$ | 76,718 | |
Contract
revenues from collaborations | |
| 6,153 | | |
| 26,495 | | |
| 11,488 | | |
| 39,024 | |
Government
contract | |
| 100 | | |
| 2,000 | | |
| 1,100 | | |
| 4,500 | |
Total
revenues | |
| 35,792 | | |
| 51,278 | | |
| 116,882 | | |
| 120,242 | |
Costs
and expenses: | |
| | | |
| | | |
| | | |
| | |
Cost
of product sales | |
| 3,790 | | |
| 342 | | |
| 7,110 | | |
| 1,749 | |
Research
and development (see Note A) | |
| 3,186 | | |
| 15,365 | | |
| 24,522 | | |
| 60,272 | |
Selling,
general and administrative (see Note A) | |
| 26,850 | | |
| 32,172 | | |
| 105,741 | | |
| 112,451 | |
Restructuring
charges | |
| - | | |
| 1,320 | | |
| - | | |
| 1,320 | |
Total
costs and expenses | |
| 33,826 | | |
| 49,199 | | |
| 137,373 | | |
| 175,792 | |
Income
(loss) from operations | |
| 1,966 | | |
| 2,079 | | |
| (20,491 | ) | |
| (55,550 | ) |
Interest
income | |
| 678 | | |
| 429 | | |
| 2,272 | | |
| 684 | |
Interest
expense | |
| (1,907 | ) | |
| (1,107 | ) | |
| (6,872 | ) | |
| (3,707 | ) |
Net
income (loss) | |
$ | 737 | | |
$ | 1,401 | | |
$ | (25,091 | ) | |
$ | (58,573 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) per
share | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | 0.00 | | |
$ | 0.01 | | |
$ | (0.14 | ) | |
$ | (0.34 | ) |
Diluted | |
$ | 0.00 | | |
$ | 0.01 | | |
$ | (0.14 | ) | |
$ | (0.34 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares
used in computing net income (loss) per share | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 174,376 | | |
| 172,851 | | |
| 173,897 | | |
| 172,406 | |
Diluted | |
| 174,468 | | |
| 172,856 | | |
| 173,897 | | |
| 172,406 | |
| |
| | | |
| | | |
| | | |
| | |
Note
A | |
| | | |
| | | |
| | | |
| | |
Stock-based
compensation expense included in: | |
| | | |
| | | |
| | | |
| | |
Selling,
general and administrative | |
$ | 1,585 | | |
$ | 3,426 | | |
$ | 6,712 | | |
$ | 10,217 | |
Research
and development | |
| 348 | | |
| 654 | | |
| 2,094 | | |
| 2,168 | |
| |
$ | 1,933 | | |
$ | 4,080 | | |
$ | 8,806 | | |
$ | 12,385 | |
SUMMARY
BALANCE SHEET DATA
(in
thousands)
| |
As
of December 31, | |
| |
2023 | | |
2022 | |
Cash,
cash equivalents and short-term investments | |
$ | 56,933 | | |
$ | 58,206 | |
Total
assets | |
| 117,225 | | |
| 134,279 | |
Stockholders'
deficit | |
| (28,644 | ) | |
| (13,616 | ) |
v3.24.0.1
Cover
|
Mar. 05, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 05, 2024
|
Entity File Number |
0-29889
|
Entity Registrant Name |
RIGEL PHARMACEUTICALS, INC.
|
Entity Central Index Key |
0001034842
|
Entity Tax Identification Number |
94-3248524
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
611 Gateway Boulevard
|
Entity Address, Address Line Two |
Suite 900
|
Entity Address, City or Town |
South San Francisco
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94080
|
City Area Code |
650
|
Local Phone Number |
624-1100
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
RIGL
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Gráfico Histórico do Ativo
De Out 2024 até Out 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024